ReviewJournal of bone oncology2022

Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.

Benoit Cadieux et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.